Literature DB >> 15708894

Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis.

B M Spriewald1, O Witzke, R Wassmuth, R R Wenzel, M-L Arnold, T Philipp, J R Kalden.   

Abstract

BACKGROUND: Cytokines and T cell regulatory proteins play an important role in the pathogenesis of Wegener's granulomatosis (WG).
OBJECTIVE: To investigate cytokine and cytotoxic T cell antigen-4 (CTLA4) gene polymorphisms and HLA class II alleles in generalised WG.
METHODS: The distribution of cytokine and cytotoxic T cell antigen 4 (CTLA4) gene polymorphisms and HLA class II alleles was analysed in 32 patients with generalised WG and 91 healthy controls. Genotyping was carried out for HLA-DRB1 and HLA-DQB1 and for polymorphism of the genes encoding TNF alpha (-238, -308, -376), TGF beta (codon 10 and 25), IFN gamma (+874), IL6 (-174), IL10 (-592, -819, -1082), CTLA4 (-318, +49), and the (AT)(n) repeats of the CTLA4 gene. In addition, stratification analysis was carried out according to the presence (n = 15) or absence (n = 17) of end stage renal disease.
RESULTS: An increase in the IFN gamma +874 T/T (odds ratio (OR) = 3.14) and TNF alpha -238 G/A (OR = 5.01) genotypes was found in WG patients. When ESRD positive and negative patients were compared, the IFN gamma +874 A/A and the CTLA4 -318 C/C genotypes were found more often in the ESRD subgroup (OR = 10.6 and OR = 2.25). WG patients without ESRD had a higher frequency of the IL10 GCC/ACC promotor genotype (OR = 0.13) and long CTLA4 (AT)(n) repeats (OR = 0.4). No effect was seen for HLA-DR and -DQ markers.
CONCLUSIONS: Disease susceptibility and clinical course in WG may be associated with distinct polymorphisms of cytokine and CTLA4 genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708894      PMCID: PMC1755422          DOI: 10.1136/ard.2004.025809

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

1.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

Authors:  R Y Leavitt; A S Fauci; D A Bloch; B A Michel; G G Hunder; W P Arend; L H Calabrese; J F Fries; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

2.  Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  E Csernok; C H Szymkowiak; N Mistry; M R Daha; W L Gross; J Kekow
Journal:  Clin Exp Immunol       Date:  1996-07       Impact factor: 4.330

3.  Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.

Authors:  B R Lúdvíksson; M C Sneller; K S Chua; C Talar-Williams; C A Langford; R O Ehrhardt; A S Fauci; W Strober
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

Review 4.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

5.  Polymorphisms in the tumor necrosis factor genes in Wegener's granulomatosis.

Authors:  B Mascher; W Schmitt; E Csernok; E Tatsis; A Reil; W L Gross; M Seyfarth
Journal:  Exp Clin Immunogenet       Date:  1997

Review 6.  HLA genes in ANCA-associated vasculitides.

Authors:  M E Griffith; C D Pusey
Journal:  Exp Clin Immunogenet       Date:  1997

7.  Interaction of transforming growth factor beta (TGF beta) with proteinase 3.

Authors:  J Kekow; E Csernok; C Szymkowiak; W L Gross
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

8.  In vitro interactions of c-ANCA (antibodies to proteinase 3) with human endothelial cells.

Authors:  W J Mayet; E M Hermann; E Csernok; W L Gross; K H Meyer zum Büschenfelde
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

9.  Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis.

Authors:  M Schlesier; T Kaspar; J Gutfleisch; G Wolff-Vorbeck; H H Peter
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

10.  Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells.

Authors:  F Moosig; E Csernok; G Wang; W L Gross
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

View more
  12 in total

Review 1.  Genetics of ANCA-associated Vasculitides.

Authors:  Manuel F Ugarte-Gil; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

2.  Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians.

Authors:  William Abbott; Edward Gane; Ingrid Winship; Stephen Munn; Colin Tukuitonga
Journal:  Immunogenetics       Date:  2007-01-09       Impact factor: 2.846

3.  CTLA-4 and TNF-α promoter-308 A/G polymorphisms and ANCA-associated vasculitis susceptibility: a meta-analysis.

Authors:  Young Ho Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

4.  Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.

Authors:  Gang Xie; Delnaz Roshandel; Richard Sherva; Paul A Monach; Emily Yue Lu; Tabitha Kung; Keisha Carrington; Steven S Zhang; Sara L Pulit; Stephan Ripke; Simon Carette; Paul F Dellaripa; Jeffrey C Edberg; Gary S Hoffman; Nader Khalidi; Carol A Langford; Alfred D Mahr; E William St Clair; Philip Seo; Ulrich Specks; Robert F Spiera; John H Stone; Steven R Ytterberg; Soumya Raychaudhuri; Paul I W de Bakker; Lindsay A Farrer; Christopher I Amos; Peter A Merkel; Katherine A Siminovitch
Journal:  Arthritis Rheum       Date:  2013-09

Review 5.  T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?

Authors:  Benjamin Wilde; Marielle Thewissen; Jan Damoiseaux; Pieter van Paassen; Oliver Witzke; Jan Willem Cohen Tervaert
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

6.  Tumor necrosis factor-alpha gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease.

Authors:  Monika Buraczynska; Piotr Mierzicki; Kinga Buraczynska; Michał Dragan; Andrzej Ksiazek
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

7.  The association between genetic variation in interleukin-10 gene and susceptibility to Henoch-Schönlein purpura in Chinese children.

Authors:  Hui Xu; Guizhen Jiang; Hongqiang Shen; Yanxiang Pan; Junfeng Zhang; Wei Li; Jianhua Mao
Journal:  Clin Rheumatol       Date:  2017-09-30       Impact factor: 2.980

8.  Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients.

Authors:  Tarciana Grandi; Cláudia Maria Dornelles da Silva; Karine Medeiros Amaral; Paulo Dornelles Picon; Cintia Costi; Nicole Nascimento da Fré; Marilu Fiegenbaum; Tatiana Schäffer Gregianini; Christian Niel; Maria Lucia Rosa Rossetti
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-06       Impact factor: 2.743

9.  Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.

Authors:  Edward J Carr; Heather A Niederer; Julie Williams; Lorraine Harper; Richard A Watts; Paul A Lyons; Kenneth G C Smith
Journal:  BMC Med Genet       Date:  2009-12-01       Impact factor: 2.103

10.  Association of genetic polymorphisms in interferon-γ, interleukin-6 and transforming growth factor-β1 gene with oral lichen planus susceptibility.

Authors:  Maha Ali M Al-Mohaya; Lubna Al-Otaibi; Fahad Al-Harthi; Ebtissam Al Bakr; Misbahul Arfin; Abdulrahman Al-Asmari
Journal:  BMC Oral Health       Date:  2016-08-20       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.